Initial Target Product Profile & Market Opportunity

Initial market opportunity

• DNA alkylating/binding agents characterized by dose-limiting toxicities are widely used in the target cancers, suggesting that a drug with a substantially wider therapeutic window would be a major advance

• Robust CT-262 preclinical data suggest CT-262 will be efficacious in the target cancers

• Blood brain barrier studies with CT-262 are being planned to evaluate the utility in treating glioblastoma

• ​DNA alkylating agents widely used in the treatment of glioblastoma

​

• Large unmet need continues to exist in the target cancers, suggesting the potential for both accelerated regulatory approval and rapid adoption by clinicians

• Primary differentiation: Potential wide therapeutic window and highly efficacious

---

Follow-on market opportunity

• Potential first-line therapy in multiple cancer indications

• Primary differentiation: Potential ability to add to existing treatment regimens, increasing efficacy without meaningfully increasing toxicity